Senti Biosciences agrees to merger with Celadon affiliate; to retain early-stage programs
Senti Biosciences Holdings entered into a merger agreement on July 14, 2026, whereby a private affiliate of its largest stockholder, Celadon Partners, will acquire substantially all of the company's existing business and pipeline, including SENTI-202. Following the transaction, Senti will remain public with a streamlined structure, retaining intellectual property and early-stage programs focused on its Regulator Dial technology platform for Rett syndrome and armored tumor-infiltrating lymphocyte therapies. Stockholders and equity award holders will receive contingent value rights potentially paying up to $60 million in cash tied to SENTI-202 development, regulatory, and commercial milestones over seven years.
Key facts
- Celadon Partners SPV 35 Limited to acquire substantially all of Senti's existing business and pipeline through merger with Senti Holdings, Inc.
- Stockholders and equity award holders to receive contingent value rights with potential payments of up to $60 million: $10 million upon BLA filing and acceptance, $20 million upon FDA approval of BLA for SENTI-202, and $30 million upon $200 million cumulative worldwide net sales
- Merger agreement dated July 14, 2026, requires stockholder approval and Majority of the Minority Approval
- Senti to retain Regulator Dial technology platform, early-stage programs in Rett syndrome gene therapy and controllable armored TIL therapies for solid tumors
- Company expects proxy filing within 30 business days; transaction expected to close in third quarter of 2026
- Parent required to fund and purchase up to $6 million in additional Senior Secured Convertible Notes within 21 days of merger agreement
- SENTI-202 previously received FDA Regenerative Medicine Advanced Therapy (RMAT) designation; Phase 1 trial showed durable MRD-negative responses in 22-patient cohort for relapsed/refractory AML
- Celadon Partners currently beneficially owns 54.6% of company's common stock as a result of Initial Notes issuance on May 20, 2026
Why it matters
The transaction separates Senti's advanced clinical-stage asset (SENTI-202) into a private entity controlled by its largest investor while allowing the public company to refocus on two early-stage platform programs; stockholders' sole economic recovery is contingent on future milestone achievements with no guaranteed cash at closing, creating significant downside risk.
Developing story
- 15-12G
- 8-Kthis filing
Share
Derived from 8-K filed 2026-07-15. Not investment advice. View the source filing on SEC.gov →